How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,998 results for

Peripheral Neuropathy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. Full Text available with Trip Pro

Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. There are inconsistencies in the literature regarding the prevalence and assessment of chemotherapy-induced peripheral neuropathy (CIPN). This study explored CIPN natural history and its characteristics in patients receiving taxane- and platinum-based chemotherapy.Multi-country multisite (...) prevalence rates using different assessments (14.2-53.4%). Prevalence of sensory neuropathy (and associated symptom profile) was also different in each type of chemotherapy, with paclitaxel (up to 63%) and oxaliplatin (up to 71.4%) showing the highest CIPN rates in most assessments and a more complex symptom profile. Peak prevalence was around the 6-month assessment (up to 71.4%). Motor neurotoxicity was common, particularly in the docetaxel subgroup (up to 22.1%; detected by NCI-CTCAE). There were

2019 BMC Cancer

102. Diabetic neuropathy

of symptoms and deficits, involving sensory, motor, and autonomic nerve fibres, and multiple organ systems. Diabetic peripheral neuropathy is the most common chronic complication of diabetes, characterised by the presence of peripheral nerve dysfunction, diagnosed after the exclusion of other causes. Pain is the outstanding complaint in most patients, but many patients are completely asymptomatic. Treatment has traditionally focused on control of hyperglycaemia as a means of slowing progression (...) or delaying onset, on targeting potential pathogenic mechanisms, and on pain reduction. Although pain is generated principally by peripheral nerve injury, there is recent evidence that the central nervous system may play a significant role in the disinhibition and amplification of pain. Indeed, the most effective drugs in treating painful diabetic neuropathy are centrally acting. Pregabalin (a voltage-gated calcium channel modulator), duloxetine (a selective dual serotonin-noradrenaline reuptake inhibitor

2018 BMJ Best Practice

103. Quantitative Sensory Testing for the Diagnosis of Lower Extremity Peripheral Neuropathy

Quantitative Sensory Testing for the Diagnosis of Lower Extremity Peripheral Neuropathy Quantitative sensory testing for the diagnosis of lower extremity peripheral neuropathy Quantitative sensory testing for the diagnosis of lower extremity peripheral neuropathy Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Quantitative sensory testing for the diagnosis (...) of lower extremity peripheral neuropathy. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' objectives Quantitative sensory testing (QST) involves assessment of the ability to detect gradually increasing levels of pressure, vibration, cold, and/or heat to diagnose the severity and extent of different types of neuropathy. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Humans; Lower Extremity; Peripheral Nervous

2014 Health Technology Assessment (HTA) Database.

104. Calmare for chemotherapy-induced peripheral neuropathy Full Text available with Trip Pro

Calmare for chemotherapy-induced peripheral neuropathy Calmare for chemotherapy-induced peripheral neuropathy Calmare for chemotherapy-induced peripheral neuropathy Mull N, Mitchell MD, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mull N, Mitchell MD, Umscheid CA. Calmare for chemotherapy-induced peripheral neuropathy. Philadelphia: Center (...) for Evidence-based Practice (CEP). 2014 Final publication URL PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Antineoplastic Agents /adverse effects; Boronic Acids; Bortezomib; Females; Male; Middle Aged; Pain Measurement; Peripheral Nervous System Diseases /chemically induced /therapy; Pilot Projects; Pyrazines; Taxoids /adverse effects; Transcutaneous Electric Nerve Stimulation; Treatment Outcome Language Published English Country of organisation United States English summary

2014 Health Technology Assessment (HTA) Database.

105. Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico

Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico Carlos F, Ramirez-Gamez J, Duenas H, Galindo-Suarez RM, Ramos E Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of duloxetine as a first treatment for adults with diabetic peripheral neuropathy and moderate-to-severe pain. The authors concluded that duloxetine was a cost-effective intervention, in Mexico. Overall, the study was adequate

2012 NHS Economic Evaluation Database.

106. A systematic review and meta-analysis of alpha-lipoic acid in the treatment of diabetic peripheral neuropathy

A systematic review and meta-analysis of alpha-lipoic acid in the treatment of diabetic peripheral neuropathy Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

107. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials

Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

108. Severity of Neuropathy Is Associated With Long-Term Spinal Cord Stimulation Outcome in Painful Diabetic Peripheral Neuropathy: Five-Year Follow-up of a Prospective Two-Center Clinical Trial. Full Text available with Trip Pro

Severity of Neuropathy Is Associated With Long-Term Spinal Cord Stimulation Outcome in Painful Diabetic Peripheral Neuropathy: Five-Year Follow-up of a Prospective Two-Center Clinical Trial. Evidence from prospective studies for long-term treatment efficacy of spinal cord stimulation (SCS) in painful diabetic peripheral neuropathy (PDPN) is not available. We report prospective data on the effect of SCS on pain ratings, treatment success and failure, and complications during a 5-year follow-up (...) in patients with PDPN.Patients with PDPN (n = 48) were included in this prospective multicenter study. The Michigan Diabetic Neuropathy Score (MDNS) was used to assess the severity of neuropathy. Numerical rating scale (NRS) score for pain, Patient's Global Impression of Change (PGIC), and treatment success (50% reduction of NRS score or significant PGIC) during 5 years of follow-up were evaluated. Complications of SCS were reported, and associations between baseline characteristics and SCS trial success

2017 Diabetes Care

109. Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. Full Text available with Trip Pro

Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. Chemotherapy-induced peripheral neuropathy (CIPN) and associated neuropathic pain is a debilitating adverse effect of cancer treatment. Current understanding of the mechanisms underpinning CIPN is limited and there are no effective treatment strategies. In this study, we treated male C57BL/6J mice with 4 cycles of either Paclitaxel (PTX) or Oxaliplatin (OXA) over a week (...) and tested pain hypersensitivity and changes in peripheral immune responses and neuroinflammation on days 7 and 13 post 1st injection. We found that both PTX and OXA caused significant mechanical allodynia. In the periphery, PTX and OXA significantly increased circulating CD4+ and CD8+ T-cell populations. OXA caused a significant increase in the percentage of interleukin-4+ lymphocytes in the spleen and significant down-regulation of regulatory T (T-reg) cells in the inguinal lymph nodes. However

2017 PLoS ONE

110. Potential mediators of improvement in painful chemotherapy-induced peripheral neuropathy via a web-based cognitive behavioural intervention. Full Text available with Trip Pro

Potential mediators of improvement in painful chemotherapy-induced peripheral neuropathy via a web-based cognitive behavioural intervention. Preliminary evidence suggests that a self-guided cognitive and behaviourally-based pain management intervention (PROSPECT) is effective for chronic painful chemotherapy-induced peripheral neuropathy (CIPN), but its mechanism of action is unknown. The purpose of this secondary analysis was to explore if changes in anxiety, depression, sleep-related

2018 Canadian oncology nursing journal = Revue canadienne de nursing oncologique Controlled trial quality: uncertain

111. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. (Abstract)

Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. One of the complications of chemotherapy is peripheral neuropathy. Various studies have shown that potent norepinephrine and serotonin reuptake inhibitors such as gabapentin, venlafaxine and duloxetine have therapeutic effects on neuropathy. The aim of this study was to compare the effects of venlafaxine vs. duloxetine on chemotherapy-induced peripheral neuropathy.In this clinical trial (...) , cancer patients who were suffering from chemotherapy-induced peripheral neuropathy comprised the study population. They were randomly assigned to three pharmacotherapy groups including venlafaxine, duloxetine and placebo. Cranial, sensory, motor neuropathies as well as neuropathic pain were evaluated on day 1, week 2, and week 4 after enrollment.Grade of cranial, motor, sensory and neuropathic pain decreased significantly in venlafaxine and duloxetine groups. This reduction was more considerable

2018 Cancer chemotherapy and pharmacology Controlled trial quality: uncertain

112. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. (Abstract)

Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. Peripheral sensory neuropathy is the most prominently reported adverse effect of oxaliplatin. The purpose of this study was to evaluate metformin role in oxaliplatin-induced neuropathy.From November 2014 to May 2016, 40 patients with stage III colorectal cancer completed 12 cycles of FOLFOX-4 regimen. Twenty patients in the control arm received FOLFOX-4 (...) and neurotensin were significantly lower in metformin arm after the 6th and the 12th cycles.Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy.

2018 International journal of colorectal disease Controlled trial quality: uncertain

113. Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial. Full Text available with Trip Pro

Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial. 30061320 2018 09 28 1935-5548 41 10 2018 10 Diabetes care Diabetes Care Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial. e141-e142 10.2337/dc18-1254 Shin Kyung-Min KM Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon, South Korea. Lee Seunghoon S Department of Acupuncture

2018 Diabetes Care Controlled trial quality: predicted high

114. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. (Abstract)

Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. Chemotherapy-induced peripheral neuropathy (CIPN) occurs in approximately 68% of patients who receive neurotoxic chemotherapy and lasts at least 6 months post-chemotherapy in approximately 30% of individuals. CIPN is associated with decreased quality of life and functional impairments. Evidence suggests that CIPN symptoms are caused, in part, by enhanced

2018 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

115. The effects of vibro-medical insole on sensation and plantar pressure distribution in diabetic patients with mild-to-moderate peripheral neuropathy. (Abstract)

The effects of vibro-medical insole on sensation and plantar pressure distribution in diabetic patients with mild-to-moderate peripheral neuropathy. The first aim of this study was to determine the effect of a vibro-medical insole on pressure sensation and the second was to measure the effects of a vibro-medical insole with and without random noise on plantar pressure distribution in diabetic patients with mild-to-moderate peripheral neuropathy.Twenty patients with mild-to-moderate diabetic (...) to without random noise (p = 0.006).Thirty minute walking with a vibro-medical insole seems to improve pressure sensation and alter peak pressure in diabetic patients with mild-to-moderate peripheral neuropathy. This work suggests that vibro-medical insoles can be used for daily living activities and possibly decreases the risk of ulceration in diabetic neuropathy patients.Copyright © 2018 Elsevier Ltd. All rights reserved.

2018 Clinical biomechanics (Bristol, Avon) Controlled trial quality: uncertain

116. Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy: A Multicenter, Pilot, Randomized, Wait-List Controlled Trial. (Abstract)

Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy: A Multicenter, Pilot, Randomized, Wait-List Controlled Trial. The purpose of this pilot, parallel, randomized controlled trial was to examine the efficacy of a self-guided online cognitive and behaviorally-based pain management intervention (Proactive Self-Management Program for Effects of Cancer Treatment [PROSPECT]) to reduce "worst" pain for individuals with chronic painful chemotherapy-induced (...) peripheral neuropathy (CIPN). Secondary outcomes included "average" pain, nonpainful CIPN symptom severity, impression of change, and pain interference. Sixty patients with chronic painful CIPN were recruited from 5 outpatient academic and community cancer centers. Patients were randomized in a 1:1 ratio to receive either 8 weeks of PROSPECT or usual care. A 7-day electronic "worst" pain intensity diary and standardized measures of pain interference, nonpainful CIPN symptom severity, impression of change

2018 The journal of pain : official journal of the American Pain Society Controlled trial quality: uncertain

117. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Full Text available with Trip Pro

Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which includes numbness, tingling, pain, cold sensitivity, and motor impairment in the hands and feet. CIPN is a dose-limiting toxicity, potentially increasing mortality. There are no FDA-approved drugs (...) randomized to chemotherapy or chemotherapy plus Exercise for Cancer Patients (EXCAP©®). EXCAP is a standardized, individualized, moderate-intensity, home-based, six-week progressive walking and resistance exercise program. Patients reported CIPN symptoms of numbness and tingling and hot/coldness in hands/feet (0-10 scales) pre- and post-intervention. We explored baseline neuropathy, sex, age, body mass index, cancer stage, and cancer type as possible factors associated with CIPN symptoms and exercise

2018 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Controlled trial quality: uncertain

118. A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy. (Abstract)

A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy. Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect of cancer treatment, potentially leading to early cessation of chemotherapy, enduring symptoms and long-lasting disability. Evidence from preclinical and clinical studies suggests that duloxetine, a serotonin-noradrenaline reuptake inhibitor, may (...) be effective in the symptomatic treatment of CIPN. This double blind, placebo controlled, phase II randomised cross-over trial aims to determine whether treatment with duloxetine results in a reduction in chronic neuropathic symptoms experienced as a result of neurotoxic chemotherapy treatment.Participants who have received neurotoxic chemotherapy and experience daily symptoms as a consequence of peripheral neuropathy will be randomly allocated to control or experimental group with a 1:1 allocation

2018 Contemporary clinical trials Controlled trial quality: predicted high

119. Cold therapy to prevent paclitaxel-induced peripheral neuropathy. (Abstract)

Cold therapy to prevent paclitaxel-induced peripheral neuropathy. This case-control study was designed to assess the efficacy of cryotherapy to prevent paclitaxel-induced painful peripheral neuropathy in women with breast cancer.Participants served as their own paired control, with randomization of the cooled glove/sock to either the dominant or the non-dominant hand/foot, worn for 15 min prior to, during, and 15 min after completion of the paclitaxel infusion. Outcome measures included (...) %) declined further participation at some point during the trial. Only seven participants (24%) were available for the final post-chemotherapy QST and questionnaires. There were no significant differences in measures of neuropathy or pain between treated and untreated hands or feet.Strategies to prevent painful peripheral neuropathy are urgently needed. In this current trial, dropout due to discomfort precluded adequate power to fully understand the potential benefits of cryotherapy. Much more research

2018 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Controlled trial quality: uncertain

120. [Warming acupuncture combined with conventional acupuncture for diabetic peripheral neuropathy with syndrome of (Abstract)

[Warming acupuncture combined with conventional acupuncture for diabetic peripheral neuropathy with syndrome of To compare the clinical efficacy differences between warming acupuncture and conventional acupuncture for diabetic peripheral neuropathy (DPN) with syndrome of yang deficiency and cold coagulation, obstruction of collaterals and blood stasis.A total of 64 patients were randomly divided into a warming acupuncture group and a conventional acupuncture group, 32 cases in each one. Based

2018 Zhongguo zhen jiu = Chinese acupuncture & moxibustion Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>